To: Director of IHS Maternal & Child Health Program
   IHS Area Chief Medical Officers
   IHS Area Immunization Coordinators
   Tribal Epidemiology Centers

From: Amy Groom, IHS Immunization Program Manager

Subject: First Quarter FY 2009 Immunization Report (October 1, 2008 – December 31, 2008)
Date: February 6th, 2009

The Indian Health Service, Tribal and Urban Indian immunization programs report on the
immunization status of American Indian and Alaska Native (AI/AN) children 3-27 months of age, 19 –
35 months of age, and AI/AN adolescents 13 – 17 years of age. These reports are submitted to the
IHS Division of Epidemiology and Disease Prevention on a quarterly basis.

3-27 Month Old Report

The 3 – 27 month report is designed to help programs ensure timely vaccination and identify children
who may be falling behind so they can be brought up to date. The criteria listed below are used to
monitor coverage in the following age groups:

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Vaccines</th>
<th>Age Group</th>
<th>Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-4 months</td>
<td>• DTAP1&lt;br&gt;• IPV 1&lt;br&gt;• Hib 1&lt;br&gt;• Hepatitis B 1&lt;br&gt;• (PNE1)&lt;sup&gt;†&lt;/sup&gt;&lt;br&gt;• (ROTA1)&lt;sup&gt;†&lt;/sup&gt;</td>
<td>16-18 months</td>
<td>• DTAP 3&lt;br&gt;• IPV 2&lt;br&gt;• MMR 1&lt;br&gt;• Hib 3&lt;br&gt;• Hepatitis B 2&lt;br&gt;• (Varicella)&lt;sup&gt;†&lt;/sup&gt;&lt;br&gt;• (PNE4)&lt;sup&gt;†&lt;/sup&gt;&lt;br&gt;• (ROTA3)&lt;sup&gt;†&lt;/sup&gt;</td>
</tr>
<tr>
<td>5-6 Months</td>
<td>• DTAP 2&lt;br&gt;• IPV 2&lt;br&gt;• Hib 2&lt;br&gt;• Hepatitis B 2&lt;br&gt;• (PNE2)&lt;sup&gt;†&lt;/sup&gt;&lt;br&gt;• (ROTA2)&lt;sup&gt;†&lt;/sup&gt;</td>
<td>19-23 months</td>
<td>• DTAP 4&lt;br&gt;• IPV 3&lt;br&gt;• MMR 1&lt;br&gt;• Hib 3&lt;br&gt;• Hepatitis B 3&lt;br&gt;• (Varicella)&lt;sup&gt;†&lt;/sup&gt;&lt;br&gt;• (PNE4)&lt;sup&gt;†&lt;/sup&gt;&lt;br&gt;• (ROTA3)&lt;sup&gt;†&lt;/sup&gt;</td>
</tr>
<tr>
<td>7-15 months</td>
<td>• DTAP 3&lt;br&gt;• IPV 2&lt;br&gt;• Hib 2&lt;br&gt;• Hepatitis B 2&lt;br&gt;• (PNE3)&lt;sup&gt;†&lt;/sup&gt;&lt;br&gt;• (ROTA3)&lt;sup&gt;†&lt;/sup&gt;</td>
<td>24-27 months</td>
<td>• DTAP 4&lt;br&gt;• IPV 3&lt;br&gt;• MMR 1&lt;br&gt;• Hib 3&lt;br&gt;• Hepatitis B 3&lt;br&gt;• (Hepatitis A1)&lt;sup&gt;†&lt;/sup&gt;&lt;br&gt;• (Varicella)&lt;sup&gt;†&lt;/sup&gt;&lt;br&gt;• (PNE4)&lt;sup&gt;†&lt;/sup&gt;&lt;br&gt;• (ROTA3)&lt;sup&gt;†&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

† Not included in Age appropriate immunization coverage calculations

Pneumococcal conjugate vaccine (PNE), rotavirus vaccine (ROTA), varicella vaccine (VAR) and
hepatitis A, though recommended, are not included in overall age appropriate coverage calculations.
Data on PNE, ROTA, VAR and hepatitis A vaccine coverage are reported where available.
Summary
For FY 2009 Q1, 12 IHS Areas submitted immunization reports from IHS, Tribal, and Urban Indian health centers (I/T/U). This composite report provides information on the immunization status of 34,154 children 3-27 months old. Of these, 24,886 or 73% received all age-appropriate vaccinations compared to 74% (24,785/33,678) of children 3-27 months in the 4th Quarter of FY 2008 [Figure 1]. Coverage by Area is included in the spreadsheet.

Figure 1

Age Appropriate Immunization Coverage
3 - 27 months
FY 2004 Q1 - FY 2009 Q1

Age appropriate coverage
Two Year Old Report

The Two year old reports (children 19-35 months old) are used to monitor progress towards the GPRA childhood immunization indicator.

The 4:3:1:3:3 series (4 DTaP, 3 IPV, 1 MMR, 3 Hib, 3 Hep B) and 4:3:1:3:3:1 (4 DTaP, 3 IPV, 1 MMR, 3 Hib, 3 Hep B, 1 VAR) are used to monitor coverage in this age group; the HP 2010 and GPRA goal is 80% with these 2 series.

4:3:1:3:3 Series

For FY 2009 Q1 the 12 IHS Areas combined reported on 25,663 two year olds. Of these 20,047, or 78%, had completed the 4:3:1:3:3 series compared to 79% (19,889/25,207) in FY 2008 Q4. [Figure 2]. Coverage by Area is included in the spreadsheet.

Figure 2

4:3:1:3:3 Coverage
2 Year Olds

![Graph showing 4:3:1:3:3 coverage for 2 year olds from FY04 Q3 to FY09 Q1]

- [FY04 Q3 (GPRA 04)]
- [FY05 Q2]
- [FY05 Q3 (GPRA 05)]
- [FY06 Q4]
- [FY06 Q5 (GPRA 06)]
- [FY07 Q6 (GPRA 07)]
- [FY08 Q7 (GPRA 2008)]
- [FY09 Q8 (GPRA 09)]
- [FY09 Q9]
- [FY10 Q0]

[4:3:1:3:3]
4:3:1:3:3:1 Series
In FY 2009 Q1, 76% (19,591/25,663) of two year olds had completed the 4:3:1:3:3:1 vaccine series compared to 77% (19,436/25,207) in FY 2008 Q4 [Figure 3]. Coverage by Area is included in the spreadsheet.

Figure 3

4:3:1:3:3:1 Coverage
2 Year Olds

- FY 05 Q3
- FY 05 Q4
- FY 06 Q1
- FY 06 Q2
- FY 06 Q3
- FY 07 Q1
- FY 07 Q2
- FY 07 Q3
- FY 08 Q1
- FY 08 Q2
- FY 08 Q3
- FY 08 Q4
- FY 09 Q1
Adolescent Report

The Adolescent Immunization Report was collected for the first time in FY 2008 Q1. This report collects data on adolescents 13 – 17 years and is designed to monitor uptake of “recently” recommended adolescent vaccines (e.g. tetanus toxoid, reduced diphtheria toxoid and acellular pertussis [Tdap], meningococcal conjugate [MCV4], and human papillomavirus [HPV] vaccines) and monitor coverage in the adolescent population with the following recommended childhood vaccines: 1 dose of Td or Tdap, 3 doses of hepatitis B, 2 doses of MMR, 2 doses of Varicella/Hx of chickenpox. A summary of immunization coverage for 13 year olds and 13 –17 year olds with these vaccines is included below.

Immunization Coverage with Tdap and MCV4 for 13 year olds, Males and Females

The ACIP recommendation for the routine administration of Tdap vaccine to adolescents was passed in June 2005. The ACIP recommendation for the routine administration of MCV4 vaccine to adolescents was passed in February 2005. The preferred age for the administration of these vaccines is 11 – 12 years of age.

For FY 2009 Q1 the 12 IHS Areas combined reported on 12,143 thirteen year olds compared to 11,589 thirteen year olds in FY 2008 Q4. Of those, 73% (8,917/12,143) had received 1 dose of Tdap vaccine, 81% (9,862/12,143) had received 1 dose of Tdap/Td vaccine and 61% (7,422/12,143) had received 1 dose of MCV4 vaccine. By comparison, in FY 2008 Q4 70% (8,151/11,589) of 13 year olds had received 1 dose of Tdap vaccine, 80% (9,319/11,589) received 1 dose of Tdap/Td vaccine and 57% (6,573/11,589) had received 1 dose of MCV4 vaccine. [Figure 4].

In FY 2009 Q1, coverage by Area ranged from 49% - 84% for Tdap, 56% - 90% for Tdap/Td, and 31% - 80% for MCV4. Coverage by Area is included in the spreadsheet.

Figure 4

Tdap, Tdap/Td, and MCV4 Coverage for 13 year olds
Immunization Coverage for 13 – 17 year olds, Males and Females

For FY 2009 Q1 the 12 IHS Areas combined reported on 59,856 13 – 17 year olds compared to 56,380 in FY 2008 Q4. Of those, 85% (50,948/59,856) had received 3 doses of hepatitis B vaccine, 88% (52,391/59,856) had received 2 doses of MMR vaccine, 65% (38,784/59,856) had received 2 doses of Varicella vaccine or had a documented history of chickenpox, 53% (31,888/59,856) had received 1 dose of Tdap vaccine, 84% (50,468/59,856) had received 1 dose of Tdap or Td and 58% (34,879/59,856) had received 1 dose of MCV4 vaccine. Coverage by Area are included in the spreadsheet.

For FY 2008 Q4, coverage for 13 – 17 years olds was as follows: 85% (47,780/56,380) with 3 doses of hepatitis B vaccine; 88% (49,368/56,380) with 2 doses of MMR; 62% (35,186/56,380) with 2 doses of Varicella or history of chickenpox; 49% (27,625/56,380) with 1 dose of Tdap vaccine; 84% (47,572/56,380) with 1 dose of Tdap/Td; and 53% (29,833/56,380) with 1 dose of MCV4 vaccine [Figure 5].

Figure 5

Immunization Coverage for 13 - 17 year olds

HPV Coverage for 13 – 17 year olds, Females Only

The ACIP recommendation for the routine administration of HPV vaccine was passed in June 2006. Routine vaccination is recommended for 11 – 12 year olds, with catch up vaccination for 13 – 26 year olds.

For FY 2009 Q1 the 12 IHS Areas combined reported on 32,361 females 13 – 17 years of age compared to 30,182 in FY 2008 Q4. Of these, 55% (17,938/32,361) had received 1 dose of HPV, 36% (11,659/32,361) had received 2 doses of HPV and 18% (5,790/32,361) had received 3 doses of HPV.

For FY 2008 Q4, 51% (15,495/30,182) of females received 1 dose of HPV, 30% (9,125/30,182) received 2 doses of HPV, and 15% (4,600/30,182) received 3 doses of HPV [Figure 6].

For FY 2009 Q1, Coverage by Area ranged from 44% - 82% for HPV1, 28% - 57% for HPV2, and 14 – 33% for HPV 3. Complete data by Area are included in the spreadsheet.
Figure 6

HPV Coverage for Females 13 - 17 years